An orally bioavailable pyrrolinone inhibitor of HIV-1 protease: computational analysis and X-ray crystal structure of the enzyme complex.
Smith
A B
AB
Department of Chemistry, University of Pennsylvania, Philadelphia 19104, USA.
Hirschmann
R
R
Pasternak
A
A
Yao
W
W
Sprengeler
P A
PA
Holloway
M K
MK
Kuo
L C
LC
Chen
Z
Z
Darke
P L
PL
Schleif
W A
WA
D000284:Administration, Oral; D000998:Antiviral Agents / Q000008:administration & dosage / Q000737:chemistry* / Q000493:pharmacokinetics; D001682:Biological Availability; D018360:Crystallography, X-Ray; D004151:Dipeptides / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics; D015195:Drug Design; D016333:HIV Protease / Q000378:metabolism*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000737:chemistry* / Q000493:pharmacokinetics; D006860:Hydrogen Bonding; D019469:Indinavir / Q000737:chemistry; D007211:Indoles / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics; D008958:Models, Molecular; D008970:Molecular Weight; D011487:Protein Conformation; D011758:Pyrroles / Q000008:administration & dosage / Q000737:chemistry* / Q000493:pharmacokinetics
D000998:Antiviral Agents; D004151:Dipeptides; D017320:HIV Protease Inhibitors; D007211:Indoles; D011758:Pyrroles; C074651:L 685434; D019469:Indinavir; D016333:HIV Protease